Alkermes to Report Q4 2025 & 2026 Outlook – Feb 25, 2026

Alkermes plc (Nasdaq: ALKS) announced it will hold a conference call and webcast on February 25, 2026, to discuss its fourth quarter and full-year 2025 financial results. The company, a global biopharmaceutical firm focused on neuroscience, will also outline its financial outlook for 2026 and provide a general business update.

The presentation is scheduled to start at 8:00 a.m. Eastern Time (1:00 p.m. Greenwich Mean Time). Investors and interested parties can access the webcast, along with accompanying slides, through the Investors section of Alkermes’ corporate website at www.alkermes.com.

For those preferring to participate via telephone, the conference call can be accessed by dialing +1 877 407 2988 for callers within the United States, and +1 201 389 0923 for international callers. A recorded replay of the webcast will be made available approximately two hours after the event concludes, also on the Alkermes website.

Alkermes develops and commercializes proprietary medicines for a range of neurological and psychiatric conditions, including alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company’s research and development pipeline focuses on neurological disorders such as narcolepsy and idiopathic hypersomnia. Alkermes maintains its headquarters in Ireland, with a significant corporate office and research facility in Massachusetts, and a manufacturing plant located in Ohio.

Jamie Constantine, Investor Relations at Alkermes, is the designated contact for investor inquiries, and can be reached at +1 781 873 2402.

The announcement follows a recent surplus property auction hosted by Jefferson Parish (.gov), and separate reports of account disruptions experienced by two St. Johns County mothers regarding Meta platforms, according to news reports published February 11, 2026. Hopewell Township municipal offices will be closed February 12, 2026, according to a separate announcement.